文献速递创伤与烧伤复苏、休克与脓毒症重症综合管理与镇静镇痛

创伤后早期抗凝血酶耗竭与内皮病及全身蛋白丢失生物标志物相关:一项回顾性观察研究

Early antithrombin depletion after trauma is associated with biomarkers of endotheliopathy and systemic protein loss: a retrospective observational study.
PubMed 文献 · Shock · 2026-09-09
一句话结论创伤入院时抗凝血酶活性<80%见于32%成人患者,与休克和DIC独立相关,且与白蛋白正相关、与SDC-1负相关,提示内皮损伤和蛋白丢失机制。

单中心回顾性观察研究纳入100例成人创伤患者,入院时检测抗凝血酶(AT)活性、白蛋白、syndecan-1(SDC-1)和凝血酶-抗凝血酶复合物(TAT)。32%患者AT活性<80%,校正年龄、性别、ISS和乳酸后,低AT仍与休克(调整OR 9.42,95%CI 1.32-109.00)和DIC(调整OR 12.20,95%CI 2.17-113.00)相关。AT活性与白蛋白正相关、与SDC-1和TAT负相关;正则化回归中白蛋白和SDC-1与AT活性关联更一致,TAT未被选入。结论提示创伤后早期AT耗竭不仅由凝血酶消耗引起,还与内皮损伤和循环蛋白丢失相关。

要点

  • 成人创伤患者入院时AT活性<80%者占32%,该阈值下休克和DIC风险显著升高。
  • 校正年龄、性别、ISS和乳酸后,低AT与休克独立相关(调整OR 9.42,95%CI 1.32-109.00,p=0.037)。
  • 校正后低AT与DIC独立相关(调整OR 12.20,95%CI 2.17-113.00,p=0.010)。
  • AT活性与白蛋白正相关、与SDC-1和TAT负相关;正则化回归中白蛋白和SDC-1关联更一致,TAT未被选入。
  • 早期AT耗竭可能反映内皮损伤和全身蛋白丢失,而非单纯凝血酶消耗。

适用人群与场景

  • 单中心回顾性观察研究纳入的100例成人创伤患者,于入院时采集残余血样检测。

诊断标准与关键阈值

  • AT活性降低定义为<80%,AT活性保留定义为≥80%。
  • 休克和DIC为临床结局,原文未给出具体诊断标准或评分界值。

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 创伤入院时AT活性<80%与休克(调整OR 9.42)和DIC(调整OR 12.20)独立相关,提示需警惕不良早期损伤表型。

研究设计与关键结果

  • 研究类型:单中心回顾性观察研究;样本量:100例成人创伤患者;无多中心信息。
  • 干预与对照:无干预,比较AT活性降低(<80%)与保留(≥80%)患者的临床结局。
  • 主要终点结果:低AT与休克调整OR 9.42(95%CI 1.32-109.00,p=0.037)、DIC调整OR 12.20(95%CI 2.17-113.00,p=0.010)独立相关,校正年龄、性别、ISS和乳酸。
  • 关键次要终点:AT活性与白蛋白正相关、与SDC-1和TAT负相关;正则化回归中白蛋白和SDC-1更一致关联AT活性,TAT未被选入;贝叶斯分析表明白蛋白和SDC-1的方向性证据强于TAT。
  • 不良事件:原文未提及。

证据类型、等级与局限

  • 证据类型:回顾性观察研究(单中心)。
  • 证据等级或推荐强度:原文未提及。
  • 局限:单中心、回顾性、样本量100例、残余血样检测、观察性设计不能推断因果;原文未提及其他局限。

对床旁实践的改变

  • 对成人创伤患者,入院时AT活性<80%可作为识别休克和DIC高风险患者的早期生物标志物线索,但原文未推荐基于AT活性启动替代治疗。
  • AT活性与白蛋白、SDC-1的关联提示内皮损伤和蛋白丢失机制,可能帮助理解创伤后凝血病,但不改变现有复苏或凝血管理流程。
  • 适用人群为成人创伤患者;原文未提及儿科、孕妇或非创伤人群的适用性。
  • 常见陷阱:不能将AT活性<80%直接等同于需要补充抗凝血酶或血浆,原文未提供此类干预证据;观察性关联不能作为决策阈值。

指南或共识出处

  • 原文未提及指南或共识名称;文献标题:Early antithrombin depletion after trauma is associated with biomarkers of endotheliopathy and systemic protein loss: a retrospective observational study.

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Early antithrombin (AT) depletion after trauma may result from thrombin-related consumption, vascular leakage, and systemic protein loss. We examined the biomarker profile associated with early AT depletion and whether reduced AT activity identifies an adverse early injury phenotype.

METHODS: In this single-center retrospective observational study, 100 adult trauma patients were analyzed on admission. AT activity, albumin (Alb), syndecan-1 (SDC-1), and thrombin-antithrombin complex (TAT) were measured in residual blood samples obtained at hospital arrival. Associations among biomarkers were assessed using locally estimated scatterplot smoothing and generalized additive models. LASSO and elastic-net regression identified variables associated with AT activity, and exploratory Bayesian regression assessed directional associations. Clinical outcomes were compared between patients with reduced (<80%) and preserved (≥80%) AT activity.

RESULTS: Reduced AT activity was present in 32% of patients and remained associated with shock (adjusted OR 9.42, 95% CI 1.32-109.00, p=0.037) and disseminated intravascular coagulation (DIC) (adjusted OR 12.20, 95% CI 2.17-113.00, p=0.010) after adjustment for age, sex, ISS, and lactate. AT activity was positively associated with Alb and negatively associated with SDC-1 and TAT. In regularized regression, Alb and SDC-1 were more consistently associated with AT activity, whereas TAT was not selected. Bayesian analyses showed stronger directional evidence for Alb and SDC-1 than for TAT.

CONCLUSION: Early AT depletion after trauma was associated with adverse clinical features and biomarker patterns consistent with endothelial injury and circulating protein depletion, beyond thrombin-related consumption alone.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Matsumoto H, Kan A, Takezawa M, et al. Early antithrombin depletion after trauma is associated with biomarkers of endotheliopathy and systemic protein loss: a retrospective observational study. Shock. 2026. PMID: 42713784. doi:10.1097/SHK.0000000000002935

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。